| Literature DB >> 34873634 |
Lars Lindberg1,2.
Abstract
The surgical repair of congenital heart defects in children with preoperative pulmonary hypertension (PH) is to varying degree associated with the occurrence of postoperative PH. The objective of this study was to follow up children with severe postoperative PH (pulmonary arterial/aortic pressure ratio ≥ 1.0) to evaluate if pulmonary arterial pressure spontaneously normalized or needed PH-targeting therapy and to identify potential high-risk diagnoses for bad outcome. Twenty-five children who developed clinically significant severe PH on at least three occasions postoperatively were included in the follow-up (20-24 years). Data from chart reviews, echocardiographic investigations, and questionnaires were obtained. Three children died within the first year after surgery. Three children were lost to follow-up. The remaining 17 children normalized their pulmonary arterial pressure without the use of PH-targeting drugs at any time during the follow-up. Two children had a remaining mild PH with moderate mitral valve insufficiency. All three children with bad outcome had combined cardiac lesions causing post-capillary pulmonary hypertension. Normalization of the pulmonary arterial pressure occurred in almost all children with severe postoperative PH, without any need of supplemental PH-targeting therapies. All children with bad outcome had diagnoses conformable with post-capillary PH making the use of PH-targeting therapies relatively contraindicated. These data emphasize the need to perform randomized, blinded trials on the use of PH-targeting drugs in children with postoperative PH before accepting it as an indication for routine treatment.Entities:
Keywords: Congenital heart disease; Pediatric cardiac surgery; Pulmonary artery pressure; Pulmonary hypertension
Mesh:
Year: 2021 PMID: 34873634 PMCID: PMC9005410 DOI: 10.1007/s00246-021-02794-9
Source DB: PubMed Journal: Pediatr Cardiol ISSN: 0172-0643 Impact factor: 1.655
Fig. 1Flowchart showing numbers of patients at each stage of their course after surgery. PH Pulmonary hypertension, PA pulmonary arterial, PICU pediatric intensive care unit, AVSD atrioventricular septal defect, MPAP mean pulmonary arterial blood pressure, MSAP mean systemic arterial blood pressure, MAP mean arterial blood pressure
Clinical characteristics of the studied children (n = 25) with perioperative severe pulmonary hypertension and their follow-up data
| Age | Weight | Syndrome | Diagnosis | Cath/Ang | Operation | PICU | PHC | INO | PHDD | Postoperative UCG | Outcome | Medication |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 m | 4.3 | Down | C AVSD, Large unrestricted VSD | No | Two-patch technique | LV-failure | YES | No | OK | Survived | Levaxin | |
| 3 m | 4.8 | Down | C AVSD + MR + double orifice Large ASD and unrestricted VSD | No | Two-patch technique | MR | YES | No | OK | Survived | No | |
| 4 m | 4.7 | Down | C AVSD + MR Large unrestricted VSD | No | Two-patch technique | No | Min MR, No TR | Survived | No | |||
| 16 m | 8.3 | C AVSD, Large ASD and moderately large VSD; PVRI 13.2 Wood U x m2; Qp/Qs 1.7/1 | Yes | Two-patch technique | No | Min MI,TR pv 2.7 m/s, minimal residual VSD | Survived | No | ||||
| 4y | 12.4 | MR + MS (post endocarditis) PWCP 27 mm Hg, PAP 88/59, AP 94/67 mm Hg | Yes | Mitroflow 23 | No | Reop MS, Min TR, EF reduced | Survived | Enalapril, Warfarin | ||||
| 13 m | 7.6 | Supravalv MS + parachute valve + VSD PSAP 70, SAP 70, LAP 16 mm Hg | Yes | Membrane res + commissurotomy | MR | YES | No | Min MR, TR peak vel 2.6 m/s | Survived | No | ||
| 3y | 12.6 | MR + left pulmonary vein stenosis PVRI 7 Wood Unit x m2 | Yes | Valvuloplasty of mitral valve | YES | No | Reop SAS, Min MR, MS, AS | Survived | No | |||
| 4d | 3.4 | TAPVD + Hypoplastic LV + obstructive PV, Systemic RV pressure | Yes | Correction of TAPVD | RV-failure | No | Min TR, Normal PAP | Survived | No | |||
| 2y | 8.9 | Supravalvular MS + VSD PCWP 20 mm Hg, PAP 54/23 mm Hg | Yes | Resection of membrane | No | Reop Coa, MR, TR with pv 3 m/s | Survived | Furosemide, Salbutamol | ||||
| 3 m | 4.2 | TGA + Large unrestrictive VSD | Yes (BAS) | Arterial switch + VSD closure | LV-failure | YES | YES | No | Stenosis in right PA | Survived | No | |
| 5 m | 5.7 | Down | C AVSD, Large unrestrictive VSD, MR | No | Two-patch technique | No | Mod MR, TR peak vel 3 m/s | Survived | ||||
| 3 m | 4.4 | Down | C AVSD + PDA + CoA | No | Two-patch technique | LV-failure + MR | No | OK | Survived | Levaxin | ||
| 1 m | 3.9 | Down | ASD + PH + VCS sin; SaO2 86–87% | No | ASD closure | No | OK | Survived | ||||
| 3 m | 3.8 | VACTERL | TAPVD + 3 VSDs, PA – systemic pressure; Large unrestrictive VSD | Yes | TAPVD closure + VSD closure | No | OK | Survived | ||||
| 9d | 2.8 | TGA | No | Arterial switch | Thrombosis VCS | YES | No | Min TR peak vel 2.3 m/s | Survived | Baclofen infusion | ||
| 2y | 8.3 | Down | Unbalanced C AVSD, single papillary muscle, PH | No | Two-patch technique | YES | No | OK | Survived | No | ||
| 6 m | 6.2 | Down | C AVSD, Large unrestrictive VSD | No | Two-patch technique | LV-failure | No | Min MR, no TR | Survived | No | ||
| 3 m | 6.2 | Unbalanced C AVSD | No | Two-patch technique | RV-failure | No | Min MR and MS | Survived | No | |||
| 6 m | 7 | TGA + VSD + Mitral straddling | Yes | Arterial switch + VSD closure | No | Moderate AR | Survived | No | ||||
| 13 m | 7.8 | Down | VSD, ASD, Qp/Qs 2.4:1 | Yes | VSD and ASD closure | LTFU | ||||||
| 4 m | 5.1 | VSD, parachute Mitral valve | No | Dividing papillary muscle division, VSD closure | Reop × 3 | LTFU | ||||||
| 3 m | 4.9 | Down | C AVSD, CoA PVRI 11.2 Wood Unit x m2; Qp/Qs 0.7:1 | Yes | Two-patch technique | LTFU | ||||||
| 7w | 4.6 | Down | Hypoplastic LV and mitral valve + ASD | No | Exploration of mitral valve + ASD closure | Severe MR, prolonged vent | YES | No | Severe MR | POD 218 | ||
| 4 m | 5.8 | Down | Unbalanced C AVSD | No | Two-patch technique | RV-failure, arrhythmia | YES | No | EF reduced | POD 205 | ||
| 4 m | 3.9 | Hypoplastic LV and MS | No | Exploration of mitral valve + papillary muscle division | Inoperable, Severe MR | No | Severe MR | POD 211 |
Age; d days, w weeks, m months, y years, AR Aortic regurgitation, AS Aortic stenosis, ASD atrial septal defect, BAS balloon atrial septostomy, Cath/Ang catheterization/angiography, CoA Coarctatio of aorta, C AVSD Complete atrioventricular septal defect, dx dexter, EF Ejection fraction, Hg Mercury, INO Inhaled Nitric oxide, LTFU Lost to follow-up, LV Left ventricle, M mitral, Min minimal, MR Mitral valve regurgitation, MS Mitral valve stenosis, obstr Obstruction, OK normal, PAP Pulmonary arterial pressure, PSAP Pulmonary systolic arterial pressure, PCWP pulmonary capillary wedge pressure, PDA Persistent ductus arteriosus, PH pulmonary hypertension, PHC Pulmonary hypertensive crisis, PHDD Pulmonary hypertensive dilating drugs, PICU pediatric intensive care unit, POD postoperative day, pv peak velocity, PV Pulmonary venous, PVRI pulmonary vascular resistance index, Qp pulmonary blood flow, Qs systemic blood flow, Res. Resection, RV Right ventricle, SAP systemic arterial pressure, SAS Subaortic stenosis, TAPVD Total anomalous pulmonary venous drainage, TGA Transposition of the great arteries, TR Tricuspid valve regurgitation, UCG Ultrasound cardiography, VACTERL Syndrome stands for Vertebral defects, Anal atresia, Cardiac defects, Tracheo-esophageal fistula, Renal anomalies, and Limb abnormalities; VCS Vena cava superior, VSD ventricle septal defect; Weight (kg)